AUTONOMIX MEDICAL INC (AMIX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$1.52-5.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · AMIX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
ex_1009345.htm Exhibit 99.1 Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules THE WOODLANDS, TX, August 24, 2026 (GLOBE NEWSWIRE) -- Auton…
Stated in a supplied disclosure. Management reported: “333-297760). The gross proceeds from the exercise of the warrants are expected to be approximately $4.9 million, prior to deducting financial advisory fees and estimated offering expenses.” “In consideration for the immediate exercise of the existing warrants in cash, the Company also agreed to issue to the Investor unregistered Series E-1 warrants to purchase an aggregate of 535,913 shares of the Company’s common stock, and unregistered Series E-2 warrants to purchase an aggregate of 535,913 shares of the Company’s common stock (collectively, the “New Warrants”).”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
We are thrilled to have her strategic insight as we work to advance Autonomix toward clinical development and ultimately position the Company for broader industry partnerships.”
Stated in a supplied disclosure. Management reported: “As a Board Member, Ms. Kalter will provide strategic guidance to Autonomix’s Board and management team as the Company advances its proprietary technologies and evaluates opportunities to expand its technology across additional therapeutic applications.” “We are thrilled to have her strategic insight as we work to advance Autonomix toward clinical development and ultimately position the Company for broader industry partnerships.””
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution.
Stated in a supplied disclosure. Management reported: “We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution.” “Our technology is investigational and has not yet been cleared for marketing in the United States.”
Continue managing capital allocation including warrant inducement agreements and modifications of security holder rights.
Maintain focus on managing operating losses and cash burn to sustain operations.
Over the trailing year it converted 0.79x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, long-term interest rates, real (inflation-adjusted) rates, the US dollar, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.